Royce & Associates LP Sells 13,001 Shares of Halozyme Therapeutics, Inc. $HALO

Royce & Associates LP reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,028 shares of the biopharmaceutical company’s stock after selling 13,001 shares during the quarter. Royce & Associates LP owned 0.06% of Halozyme Therapeutics worth $5,429,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Handelsbanken Fonder AB lifted its holdings in shares of Halozyme Therapeutics by 82.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 388,369 shares of the biopharmaceutical company’s stock worth $28,483,000 after acquiring an additional 176,000 shares during the last quarter. Diversify Wealth Management LLC raised its position in Halozyme Therapeutics by 3.8% in the 3rd quarter. Diversify Wealth Management LLC now owns 19,750 shares of the biopharmaceutical company’s stock worth $1,448,000 after purchasing an additional 722 shares during the period. Intech Investment Management LLC lifted its stake in Halozyme Therapeutics by 46.0% in the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock worth $10,903,000 after purchasing an additional 46,850 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Halozyme Therapeutics by 13.6% in the third quarter. EverSource Wealth Advisors LLC now owns 3,049 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 364 shares during the last quarter. Finally, Clearstead Advisors LLC boosted its position in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $53,947,690.28. This represents a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 62,000 shares of company stock valued at $4,545,200 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.9%

NASDAQ:HALO opened at $70.02 on Thursday. The company has a 50-day moving average price of $72.71 and a 200-day moving average price of $70.76. The stock has a market cap of $8.26 billion, a price-to-earnings ratio of 28.12, a P/E/G ratio of 0.28 and a beta of 0.98. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter in the prior year, the firm earned $1.26 EPS. Halozyme Therapeutics’s quarterly revenue was up 51.6% compared to the same quarter last year. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HALO. Benchmark boosted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Hold” and a consensus price target of $78.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.